The p140Cap adaptor protein in tumor progression

Paola Defilippi’s lab
Department of Molecular Biotechnology and Health Sciences
MBC1, Via Nizza 52, 10126 Torino, 011-6706434
paola.defilippi@unito.it

Breast cancer (BC) is the most frequent form of tumor in women. Every year in Italy there are around 50,000 new cases of BC. Despite consolidated therapeutic protocols, approximately 15% of patients experience drug resistance. Overexpression of the receptor tyrosine kinase ErbB2 characterizes approximately 20% of human BC. ERbB2+ and Triple Negative subtypes undergo frequent relapses and drug resistance.

Defilippi’s lab will offer to the applicant all the conditions to carry out her/his work, with innovative techniques in a centre which benefit of the facilities required to carry on the proposed research, including fully equipped cell culture, microscope and animal facility.

List of publications at: https://iris.unito.it/simple-search?query=Defilippi+Paola&rpp=10&sort_by=bi_sort_2_sort&order=DESC&filter_field_1=publtypeh&filter_type_1=equals&filter_value_1=03-CONTRIBUTO+IN+RIVISTA#.XXtJt5MzZBw%E2%80%A2IRIS

If interested, please write to paola.defilippi@unito.it for a meeting.